Search research articles
Contact Us
Filters
Showing results (131-140 of 149) with videos related to
Page
of 15
Sort By:
The Biochemical Journal
|
July 5, 2007
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity
Jun Li, Christine Tumanut, Julie-Ann Gavigan, et al.
The Biochemical Journal
|
July 17, 2010
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
Christian C Lee, Yong Jia, Nanxin Li, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 30, 2008
Discovery of inhibitors of the channel-activating protease prostasin (CAP1/PRSS8) utilizing structure-based design
David C Tully, Agnès Vidal, Arnab K Chatterjee, et al.
ACS Medicinal Chemistry Letters
|
July 21, 2016
Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors
Dai Cheng, Jun Liu, Dong Han, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
February 9, 2013
Enhanced proteolytic clearance of plasma Aβ by peripherally administered neprilysin does not result in reduced levels of brain Aβ in mice
John R Walker, Reynand Pacoma, James Watson, et al.
Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale
|
April 28, 2016
In vivo Wnt pathway inhibition of human squamous cell carcinoma growth and metastasis in the chick chorioallantoic model
Shannon F Rudy, J Chad Brenner, Jennifer L Harris, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 1, 2006
Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitors
David C Tully, Hong Liu, Arnab K Chatterjee, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 1, 2006
Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3
David C Tully, Hong Liu, Phil B Alper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2005
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
Howard A Burris, Herbert I Hurwitz, E Claire Dees, et al.
Annals of the Rheumatic Diseases
|
February 4, 2017
Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling
Chih-Wei Chen, Christian Beyer, Jun Liu, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 149) with videos related to
Sort By:
Page
of 15
The Biochemical Journal
|
July 5, 2007
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity
Jun Li, Christine Tumanut, Julie-Ann Gavigan, et al.
The Biochemical Journal
|
July 17, 2010
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
Christian C Lee, Yong Jia, Nanxin Li, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 30, 2008
Discovery of inhibitors of the channel-activating protease prostasin (CAP1/PRSS8) utilizing structure-based design
David C Tully, Agnès Vidal, Arnab K Chatterjee, et al.
ACS Medicinal Chemistry Letters
|
July 21, 2016
Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors
Dai Cheng, Jun Liu, Dong Han, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
February 9, 2013
Enhanced proteolytic clearance of plasma Aβ by peripherally administered neprilysin does not result in reduced levels of brain Aβ in mice
John R Walker, Reynand Pacoma, James Watson, et al.
Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale
|
April 28, 2016
In vivo Wnt pathway inhibition of human squamous cell carcinoma growth and metastasis in the chick chorioallantoic model
Shannon F Rudy, J Chad Brenner, Jennifer L Harris, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 1, 2006
Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitors
David C Tully, Hong Liu, Arnab K Chatterjee, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 1, 2006
Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3
David C Tully, Hong Liu, Phil B Alper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2005
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
Howard A Burris, Herbert I Hurwitz, E Claire Dees, et al.
Annals of the Rheumatic Diseases
|
February 4, 2017
Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling
Chih-Wei Chen, Christian Beyer, Jun Liu, et al.
Page
of 15